This approval marks the third endometrial carcinoma indication and the 40th indication overall for KEYTRUDA in the
The approval is based on data from the Phase 3 NRG-GY018 trial, also known as KEYNOTE-868, in which KEYTRUDA plus carboplatin and paclitaxel followed by KEYTRUDA alone reduced the risk of disease progression or death by 40% (HR=0.60 [95% CI, 0.46-0.78]; p
(C) 2024 Electronic News Publishing, source